Targeted Disease(s):
Lung Cancer
Purpose of Study:
This is a randomized Phase 2 study that will test whether the investigational study drug called telaglenastat will be safe and potentially effective when combined with the FDA approved immunochemotherapy regimen of pembrolizumab, carboplatin, and pemetrexed in treating patients with stage IV lung cancer that has a mutation in NRF2/(NFE2L2) or KEAP1 genes. Patients on this study will not have received any systemic treatment for advanced lung cancer. All patients in this study will receive the approved recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed either with or without telaglenastat.
Study Dates:
February 1, 2020 - October 31, 2024
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Calithera Biosciences
Contact:
Clinical Administrator
ClinicalTrails.gov Identifier:
NCT04265534
